Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 18,156
Companies: 1,062
Drugs tracked: 3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

Acnatac 10mg/g + 0,25mg/g Gel, Clindamycin Tretinoin Gel, Vehicle to Clindamycin Tretinoin Gel

Clinical study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and of one ointment without active substances for patients with chronic stable plaque poriasis

Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Cream (Test) vs. Lotricomb® Cream (Reference) vs. Vehicle in patients with moderate to severely inflamed candidiasis of the skin

InfectoScab® 5 % Crème, Permethrin, DRIPONIN 3 mg Tabletten

LANREOTIDE, LANREOTIDE, Debio 4126, Debio 4126, Ready-to-use suspension resembling 30, 60, or 90 mg Debio 4126 doses, Debio 4126, OCTREOTIDE, OCTREOTIDE, LANREOTIDE, OCTREOTIDE

Methylprednisolone Aceponate Cream, Advantan 0.1% cream, Vehicle to Methylprednisolone Aceponate Cream

Permethrin, InfectoScab® 5 % Crème

SanaCutan® Basiscreme

Solcera, Preserved water

Vehicle to Mecloderm Ointment, LOTRICOMB® Salbe, 0,64 mg/g + 10 mg/g, Salbe, Mecloderm Ointment

Vehicle to Test Product, Ivermectin Cream, Soolantra 10 mg/g Creme

[68Ga]Ga-PentixaFor, FLUDEOXYGLUCOSE (18F)

A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) (ACHIEVE)

Balstilimab, CR6086, CR6086

Debio 4228, Debio 4228

Radotinib HCl, Placebo for Radotinib HCl

Solution for injection in pre-filled syringe

WSD0922-FU, WSD0922-FU

[90Y]Y-PentixaTher, LysaKare 25 g/25 g solution for infusion, [68Ga]Ga-PentixaFor

A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

A first-in-human trial to evaluate safety, tolerability, and pharmacokinetics of single and multiple oral doses of Debio 1453P in healthy adults

A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors

Bioequivalence of two transdermal therapeutic systems delivering 100 mcg/h fentanyl

Bioequivalence of two transdermal therapeutic systems delivering 100 mcg/h fentanyl

Frequently asked questions